Announcement • Jun 12
An undisclosed buyer acquired 7.47% stake in Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) from Hana Pharm Co., Ltd. (KOSE:A293480) for KRW 23.4 billion. An undisclosed buyer agreed to acquire 7.47% stake in Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) from Hana Pharm Co., Ltd. (KOSE:A293480) for KRW 23.4 billion on May 14, 2026. A cash consideration of KRW 23.36 billion will be paid by the buyer. As part of consideration, KRW 23.36 billion is paid towards common equity of Samjin Pharmaceuticals Co., Ltd. The proceeds of the transaction will be used for securing funding for an investment.
An undisclosed buyer completed the acquisition of 7.47% stake in Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) from Hana Pharm Co., Ltd. (KOSE:A293480) on May 19, 2026. New Risk • May 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change). Buy Or Sell Opportunity • May 19
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 27% to ₩24,700. The fair value is estimated to be ₩20,534, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Announcement • Feb 13
Samjin Pharmaceuticals Co., Ltd., Annual General Meeting, Mar 24, 2026 Samjin Pharmaceuticals Co., Ltd., Annual General Meeting, Mar 24, 2026, at 10:00 Tokyo Standard Time. Location: happy hall, 123, wausan-ro, mapo-gu, seoul South Korea Upcoming Dividend • Dec 22
Upcoming dividend of ₩800 per share Eligible shareholders must have bought the stock before 29 December 2025. Payment date: 14 April 2026. Trailing yield: 3.9%. Within top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.8%). Declared Dividend • Nov 08
Dividend of ₩800 announced Dividend of ₩800 is the same as last year. Ex-date: 29th December 2025 Payment date: 14th April 2026 Dividend yield will be 4.0%, which is higher than the industry average of 1.1%. Sustainability & Growth The dividend has not increased over the past 4 years but payments have been stable during that time. Announcement • Nov 07
Samjin Pharmaceuticals Co., Ltd. announces Annual dividend, payable on April 14, 2026 Samjin Pharmaceuticals Co., Ltd. announced Annual dividend of KRW 800.0000 per share payable on April 14, 2026, ex-date on December 29, 2025 and record date on December 31, 2025. Buy Or Sell Opportunity • Apr 07
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 5.5% to ₩16,990. The fair value is estimated to be ₩21,293, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Announcement • Feb 18
Samjin Pharmaceuticals Co., Ltd., Annual General Meeting, Mar 21, 2025 Samjin Pharmaceuticals Co., Ltd., Annual General Meeting, Mar 21, 2025, at 10:00 Tokyo Standard Time. Location: happy hall, 123, wausan-ro, mapo-gu, seoul South Korea Upcoming Dividend • Dec 20
Upcoming dividend of ₩800 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 15 April 2025. Trailing yield: 4.4%. Within top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.1%). Declared Dividend • Nov 29
Dividend of ₩800 announced Shareholders will receive a dividend of ₩800. Ex-date: 27th December 2024 Payment date: 15th April 2025 Dividend yield will be 4.3%, which is higher than the industry average of 1.1%. Sustainability & Growth The dividend has not increased over the past 3 years but payments have been stable during that time. Buy Or Sell Opportunity • Nov 14
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 11% to ₩16,920. The fair value is estimated to be ₩21,186, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Announcement • Nov 13
Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces an Equity Buyback for KRW 5,000 million worth of its shares. Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a trust contract with Mirae Asset Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on May 12, 2025. As of November 12, 2024, the company had 1,372,620 shares in treasury within scope available for dividend and had 0 shares in treasury through other repurchase. Announcement • Jun 05
Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces an Equity Buyback for KRW 5,000 million worth of its shares. Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a trust contract with Mirae Asset Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on December 2, 2024. As of June 2, 2024, the company had 1,125,036 shares in treasury within scope available for dividend and had 0 shares in treasury through other repurchase. New Risk • Mar 16
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Upcoming Dividend • Dec 20
Upcoming dividend of ₩800 per share at 3.7% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 10 April 2024. Trailing yield: 3.7%. Within top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%). New Risk • Oct 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (7.7% increase in shares outstanding). Announcement • Jun 17
Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces an Equity Buyback for KRW 5,000 million worth of its shares. Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a trust contract with Mirae Asset Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on December 15, 2023. As of June 15, 2023, the company had 897,920 shares in treasury within scope available for dividend and had 0 shares in treasury through other repurchase. Upcoming Dividend • Dec 21
Upcoming dividend of ₩800 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 18 April 2023. Trailing yield: 3.0%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%). Announcement • Dec 03
Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces an Equity Buyback for KRW 5,000 million worth of its shares. Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a trust contract with Mirae Asset Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on June 1, 2023. As of December 1, 2022, the company had 486,067 shares in treasury within scope available for dividend and had 0 shares in treasury through other repurchase. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. CEO & Director Yong-Joo Choi was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Upcoming Dividend • Dec 22
Upcoming dividend of ₩800 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 19 April 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 3.0%. Within top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%). Is New 90 Day High Low • Mar 04
New 90-day low: ₩24,350 The company is down 9.0% from its price of ₩26,850 on 04 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 18% over the same period. Announcement • Feb 22
Samjin Pharmaceuticals Co., Ltd., Annual General Meeting, Mar 26, 2021 Samjin Pharmaceuticals Co., Ltd., Annual General Meeting, Mar 26, 2021, at 10:00 Korea Standard Time. Is New 90 Day High Low • Jan 18
New 90-day low: ₩25,550 The company is down 7.0% from its price of ₩27,400 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 16% over the same period. Upcoming Dividend • Dec 22
Upcoming Dividend of ₩800 Per Share Will be paid on the 13th of April to those who are registered shareholders by the 29th of December. The company last paid an ordinary dividend in March 2011. The average dividend yield among industry peers is 0.6%. Is New 90 Day High Low • Oct 16
New 90-day low: ₩27,200 The company is down 1.0% from its price of ₩27,500 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period.